Actively Recruiting
Surveillance, Assessment and Detection of Influenza Associated Respiratory Infections in HIV Positive and Negative Adults in Lusaka, Zambia
Led by Centre for Infectious Disease Research in Zambia · Updated on 2025-06-19
594
Participants Needed
2
Research Sites
8 weeks
Total Duration
On this page
Sponsors
C
Centre for Infectious Disease Research in Zambia
Lead Sponsor
H
Heidelberg University
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying influenza (flu) infections and related respiratory viruses in adults living in Lusaka, Zambia, where HIV is common. The research aims to understand how often influenza occurs, its types, seasonal patterns, and health outcomes, especially in people with HIV. The study also looks at co-infections with RSV and COVID-19 and how vaccination status affects these outcomes. This observational study will provide important knowledge about respiratory infections in this setting after the COVID-19 pandemic. Participants who have had flu-like symptoms for 2 to 7 days will be enrolled from two hospitals. They will provide nasal or nasopharyngeal samples and exhaled breath aerosol samples to compare testing methods. Researchers will also ask participants about their experience with the new breath sampling. Participants will be followed for 14 days to monitor symptom progression and clinical outcomes. All care provided is within routine health services. During the study, participants will complete a symptoms diary for 7 days and attend follow-up visits up to two weeks after joining. Researchers will collect data on flu prevalence, co-infections, and outcomes. The main measure is the prevalence of influenza infection over 18 months. This study runs from April 2025 to November 2026 and is sponsored by the Centre for Infectious Disease Research in Zambia.
CONDITIONS
Brief Title
SURVEILLANCE, ASSESSMENT AND DETECTION OF INFLUENZA ASSOCIATED RESPIRATORY INFECTIONS IN HIV POSITIVE AND NEGATIVE INDIVIDUALS IN LUSAKA, ZAMBIA
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Age 18 years or older
- Presenting with flu-like symptoms or acute respiratory infection with 2 to 7 days history of cough and/or sore throat and fever, with or without sneezing, congestion, muscle pain, fatigue, wheezing, or shortness of breath
- Willing to share HIV status or undergo HIV testing
- Willing to share COVID-19 vaccination status
- Able and willing to give informed consent
- Willing to provide nasal or nasopharyngeal samples for testing
- Willing to provide exhaled breath aerosol samples by wearing a mask
- Willing to fill a symptom diary card for 7 days
- Agree to be followed up and attend study visits up to two weeks after study entry
You will not qualify if you...
- Unwilling to provide any standard reference samples such as nasopharyngeal swabs
- Having symptoms for more than 7 days
- Unwilling or unable to provide informed consent
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 18 months
Participants are observed for influenza associated respiratory infections and related symptoms.
Follow-up visits up to two weeks after study entry; symptom diary card for 7 days
Trial Site Locations
Total: 2 locations
1
Chawama 1st level Hospital
Lusaka, Lusaka Province, Zambia, 10101
Actively Recruiting
2
Kanyama 1st Level Hospital
Lusaka, Lusaka Province, Zambia, 10101
Actively Recruiting
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here